Beckman Coulter Life Sciences, a worldwide chief in laboratory automation and innovation, continues to prepared the ground with next-generation sequencing (NGS) analysis options. At the moment the corporate publicizes a collaboration settlement with Pillar Biosciences, which develops and distributes IVD & RUO NGS testing options primarily based on their proprietary SLIMamp® know-how to assist localize affected person testing and optimize the collection of precision therapies for most cancers sufferers.
Picture Credit score: Beckman Coulter Life Sciences
Pillar Biosciences will develop a collection of purposes to be used on the Biomek NGeniuS Subsequent Technology Library Preparation System as a part of the settlement. Launched in June of 2022, the Biomek NGeniuS System continues to achieve a strong following in analysis because of its open-chemistry idea, user-friendly software program, and Dynamic DeckOptix System which reduces errors by figuring out misplaced labware.
The applying improvement partnership is initially targeted on 5 commercially-available, strong tumor liquid biopsy and hematology panels from Pillar Biosciences:
- oncoRevealTM Myeloid
- oncoRevealTM Stable Tumor v2
- oncoRevealTM Multi-Most cancers plus CNV
- oncoRevealTM Stable Tumor 22 Gene
- oncoRevealTM Core LBx
“Enabling prospects to attain pioneering analysis breakthroughs is paramount to what we do each day at Beckman Coulter Life Sciences,” mentioned Ewan Grant, Senior Director of Liquid Dealing with and Genomics Product Administration. “We’re elated that Pillar Biosciences has put their belief in us to ship a minimal hands-on time resolution that removes the burden of sluggish and grueling handbook library preparation, and we look ahead to what might be achieved to additional speed up solutions in most cancers analysis.”
The complexity and prices related to NGS testing are nonetheless boundaries to broader adoption. A key benefit for Pillar Biosciences is our streamlined single tube, one-day NGS workflow. Combining the simplicity of our NGS library preparation know-how with the automation capabilities of the Biomek NGeniuS System will considerably cut back error, assay prices, and hands-on time, serving to guarantee extra oncology researchers get the outcomes they want quicker, with decrease prices and higher effectivity.”
Randy Pritchard, CEO, Pillar Biosciences
The applying from Pillar Biosciences particularly designed for the Biomek NGeniuS System might be obtainable to prospects by way of a first-of-its-kind digital software library.
A presentation highlighting the analysis findings will happen on the November Affiliation for Molecular Pathology (AMP) Annual Assembly and Expo in Salt Lake Metropolis, Utah. The presentation, titled Extremely Correct and Automated (RUO) NGS Assays for Environment friendly Localized LBx and TBx Testing in Oncology will happen on Wednesday, November 15, 2023 at 9:00 a.m. MST. A scientific poster entitled Automation of the Pillar Biosciences oncoReveal Stable Tumor 22 gene panel (ORST22) on the Biomek NGeniuS Subsequent Technology Library Prep System may also be introduced on Saturday, November 18 at 9:15 a.m. MST.
With the worldwide NGS market projected to develop to just about $27 billion by 20271, demand is predicted to extend for options to offer crucial help to NGS labs. The Biomek NGeniuS System gives customers flexibility with unique software program that enables any batch dimension, from 4 to 24 samples, to be arrange from wherever and monitored remotely*. The workstation additionally reduces loading errors by combining subtle optical analytics know-how to offer customers real-time suggestions on labware placement.